PEPTIDE COMPARISON

Tesamorelin vs Tirzepatide

Indication-specific HIV-lipodystrophy evidence compared with dual-incretin metabolic evidence.

QUICK ANSWER

Tesamorelin vs Tirzepatide: the main difference.

Tesamorelin and tirzepatide are not substitutes for the same evidence question. The relevant choice starts with population and indication, not which study reports a larger body-composition change.

Decision field	Tesamorelin	Tirzepatide
Primary population	Adults with HIV and lipodystrophy	Product-specific metabolic and obstructive-sleep-apnea populations
Mechanism	GHRH analog	GIP and GLP-1 receptor agonist
FDA status	Approved for one narrow abdominal-fat indication	Approved branded products with indication-specific labels
Evidence program	Randomized trials focused on HIV-associated visceral fat	Large randomized metabolic-development programs
Main boundary	Not general weight-loss management	Different outcome, population, label, and product-quality questions

SOURCES

Tesamorelin vs Tirzepatide sources.

FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Zepbound prescribing informationU.S. FDA FDA / 2024FDA approves first medication for obstructive sleep apneaU.S. FDA

Tesamorelin vs Tirzepatide: the main difference.

Tesamorelin vs Tirzepatide sources.

Questions related to Tesamorelin vs Tirzepatide.

Compare the next decision.